Compare Stocks

→ Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$5.17 -3.7%	$6.43	$2.78 ▼ $8.85	$28.07M	1.03	29,576 shs	6,305 shs
HOOK Hookipa Pharma	$0.85 +11.1%	$0.74	$0.41 ▼ $2.05	$84.11M	1.02	697,669 shs	10.35 million shs
IMRA IMARA		$17.12	$0.97 ▼ $6.32	$165.80M	1.09	138,364 shs	271,700 shs
LBPH Longboard Pharmaceuticals	$19.75 -2.6%	$20.12	$3.60 ▼ $28.15	$711.40M	1.24	1.28 million shs	299,988 shs
ORGS Orgenesis	$0.50 -3.3%	$0.65	$0.25 ▼ $1.50	$17.24M	1.07	218,895 shs	33,681 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	+4.07%	-5.79%	-12.25%	-4.62%	+37.40%
HOOK Hookipa Pharma	+8.20%	-5.54%	+7.58%	+6.52%	-14.04%
IMRA IMARA	0.00%	0.00%	0.00%	0.00%	0.00%
LBPH Longboard Pharmaceuticals	+8.57%	+11.07%	+1.45%	-21.04%	+179.59%
ORGS Orgenesis	+2.33%	+3.80%	-42.27%	+69.17%	-52.82%

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	3.37 of 5 stars	3.5	5.0	0.0	0.0	2.2	3.3	0.6
HOOK Hookipa Pharma	3.6859 of 5 stars	3.5	5.0	0.0	0.0	4.0	1.7	1.3
IMRA IMARA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LBPH Longboard Pharmaceuticals	1.3916 of 5 stars	3.5	1.0	0.0	0.0	2.1	2.5	0.0
ORGS Orgenesis	1.3878 of 5 stars	0.0	5.0	0.0	4.4	1.8	1.7	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	199.81% Upside
HOOK Hookipa Pharma	3.00	Buy	$5.17	507.84% Upside
IMRA IMARA	N/A	N/A	N/A	N/A
LBPH Longboard Pharmaceuticals	3.00	Buy	$39.50	100.00% Upside
ORGS Orgenesis	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ORGS, IMRA, HOOK, APRE, and LBPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2024	LBPH Longboard Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
4/10/2024	LBPH Longboard Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$60.00
3/27/2024	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$9.00 ➝ $11.00
3/26/2024	APRE Aprea Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/25/2024	HOOK Hookipa Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
3/25/2024	HOOK Hookipa Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.50
3/15/2024	LBPH Longboard Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
3/13/2024	LBPH Longboard Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00
3/13/2024	LBPH Longboard Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$60.00
2/16/2024	LBPH Longboard Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
1/30/2024	HOOK Hookipa Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$580K	48.40	N/A	N/A	$4.54 per share	1.14
HOOK Hookipa Pharma	$20.13M	4.18	N/A	N/A	$0.91 per share	0.93
IMRA IMARA	N/A	N/A	N/A	75.24	$3.44 per share	N/A
LBPH Longboard Pharmaceuticals	N/A	N/A	N/A	N/A	$1.67 per share	N/A
ORGS Orgenesis	$530K	32.53	N/A	N/A	($0.66) per share	-0.76

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$14.29M	-$3.99	N/A	N/A	N/A	N/A	-65.58%	-52.37%	5/20/2024 (Estimated)
HOOK Hookipa Pharma	-$81.58M	-$0.88	N/A	N/A	N/A	-405.28%	-72.30%	-40.51%	5/9/2024 (Estimated)
IMRA IMARA	$1.49M	$0.05	126.40	N/A	N/A	N/A	2.12%	2.00%	N/A
LBPH Longboard Pharmaceuticals	-$54.42M	-$2.38	N/A	N/A	N/A	N/A	-97.53%	-85.21%	5/14/2024 (Estimated)
ORGS Orgenesis	-$55.36M	-$0.91	N/A	∞	N/A	-91.25%	-590.97%	-126.17%	5/8/2024 (Estimated)

Latest ORGS, IMRA, HOOK, APRE, and LBPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/26/2024	Q4 2023	APRE Aprea Therapeutics	-$0.56	-$0.92	-$0.36	-$0.92	$0.33 million	$0.01 million
3/22/2024	Q4 2023	HOOK Hookipa Pharma	-$0.20	-$0.11	+$0.09	N/A	$3.60 million	$7.41 million
3/12/2024	Q4 2023	LBPH Longboard Pharmaceuticals	-$0.60	-$0.62	-$0.02	-$0.62	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	N/A	N/A	N/A	N/A	N/A
IMRA IMARA	N/A	N/A	N/A	N/A	N/A
LBPH Longboard Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.13	5.13
HOOK Hookipa Pharma	N/A	3.50	3.50
IMRA IMARA	N/A	48.98	48.98
LBPH Longboard Pharmaceuticals	N/A	5.14	5.14
ORGS Orgenesis	1.48	0.25	0.25

Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
HOOK Hookipa Pharma	63.88%
IMRA IMARA	49.28%
LBPH Longboard Pharmaceuticals	63.28%
ORGS Orgenesis	22.56%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	20.90%
HOOK Hookipa Pharma	4.60%
IMRA IMARA	37.30%
LBPH Longboard Pharmaceuticals	4.64%
ORGS Orgenesis	7.14%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.43 million	4.30 million	No Data
HOOK Hookipa Pharma	56	98.95 million	94.40 million	Optionable
IMRA IMARA	41	26.23 million	16.45 million	Not Optionable
LBPH Longboard Pharmaceuticals	50	36.02 million	34.35 million	Optionable
ORGS Orgenesis	167	34.34 million	31.89 million	Optionable

ORGS, IMRA, HOOK, APRE, and LBPH Headlines

Source	Headline
	Orgenesis secures $2.3 million investment and strategic partnership investing.com - April 17 at 11:58 AM
	Orgenesis Inc.: Orgenesis Provides Year End Business Update finanznachrichten.de - April 17 at 9:28 AM
	Orgenesis Provides Year End Business Update globenewswire.com - April 15 at 5:07 PM
	Germfree partners with Orgenesis to enhance CGT production investing.com - April 11 at 7:22 PM
	Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility globenewswire.com - April 10 at 12:00 PM
	Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference globenewswire.com - March 18 at 8:30 AM
	Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes globenewswire.com - March 13 at 8:30 AM
	Orgenesis files patent for modified chimeric antigen receptor (car) molecule with enhanced anti-tumor activity pharmaceutical-technology.com - March 12 at 12:52 PM
	Registered Student Organizations utsa.edu - March 4 at 1:34 PM
	Orgenesis Inc. Announces $2.3 Million Private Placement globenewswire.com - March 4 at 8:30 AM
	Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing globenewswire.com - February 29 at 8:30 AM
	Orgenesis Inc. (ORGS) finance.yahoo.com - February 23 at 2:21 PM
	Orgenesis Inc ORGS morningstar.com - February 22 at 9:04 PM
	EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic msn.com - January 31 at 10:11 AM
	Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic finance.yahoo.com - January 31 at 10:11 AM
	Cadet Organizations ung.edu - January 19 at 11:37 PM
	Too many news orgs adopt right-wing frames about trans people niemanlab.org - January 11 at 12:04 PM
	Orgenesis Inc. (ORGS) Stock Historical Prices & Data - Yahoo Finance finance.yahoo.com - January 8 at 2:42 PM
	Religious Organizations uml.edu - January 6 at 11:27 PM
	Cisco’s AI Asst for Security to reframe orgs’ view of cybersecurity outcomes businessmirror.com.ph - December 28 at 11:31 PM
	Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon finance.yahoo.com - November 22 at 7:49 AM
	Orgenesis Inc.: Orgenesis Provides Business Update for the Third Quarter of 2023 finanznachrichten.de - November 15 at 8:44 PM
	Right-Wing Orgs are Using a Social Media Loophole to Skirt Hate-Speech Rules rollingstone.com - November 14 at 5:28 PM
	Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM finance.yahoo.com - November 14 at 9:23 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aprea Therapeutics

NASDAQ:APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Hookipa Pharma

NASDAQ:HOOK

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

IMARA

NASDAQ:IMRA

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Longboard Pharmaceuticals

NASDAQ:LBPH

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Orgenesis

NASDAQ:ORGS

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial